文献速递细菌感染、耐药与抗菌药物

头孢布烯与ledaborbactam etzadroxil无临床相关QTc延长

No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

两项随机、单中心、双盲、安慰剂对照的I期剂量递增研究,在健康成人中采用浓度-QTc建模分析头孢布烯与ledaborbactam etzadroxil对心脏复极的影响。结果显示两药均未引起临床相关的ECG参数变化,在预期治疗浓度及以上可排除超过10 ms的ΔΔQTcF效应,支持该口服复方组合的心脏安全性。

要点

  • 两药在预期治疗浓度及以上均未显示临床相关的QTc延长。
  • 头孢布烯可见心率轻度一过性升高,无临床意义。
  • 结果为该口服固定剂量组合的心脏安全性提供支持。

核心结论

  • 头孢布烯与ledaborbactam etzadroxil对心脏复极及ECG参数无临床相关影响。
  • 浓度-QTc分析在预期治疗浓度及以上排除了有临床意义的QTc效应,支持该口服固定剂量组合的心脏安全性。

研究设计与样本

  • 两项随机、单中心、双盲、安慰剂对照的I期剂量递增研究,受试者为健康成人(NCT04314206、NCT04243863)。
  • 头孢布烯研究纳入36人(27例活性药、9例安慰剂),ledaborbactam etzadroxil研究纳入48人(36例活性药、12例安慰剂),采用浓度-QTc建模分析。

主要发现

  • 两药均未产生临床相关的ECG参数变化,血浆浓度与ΔΔQTcF间无统计学或临床有意义的关系。
  • 在顺式头孢布烯44 µg/mL、反式头孢布烯2.2 µg/mL、ledaborbactam 30.3 µg/mL、ledaborbactam etzadroxil 2.6 µg/mL浓度下可排除ΔΔQTcF超过10 ms的效应。
  • 头孢布烯可见心率轻度、一过性、无临床意义的升高,ledaborbactam etzadroxil对心率无临床有意义的影响。

关键数值与推荐

  • 监管阈值:ΔΔQTcF超过10 ms视为需排除的效应。
  • 可排除超过10 ms效应的血浆浓度上限:顺式头孢布烯44 µg/mL、反式头孢布烯2.2 µg/mL、ledaborbactam 30.3 µg/mL、ledaborbactam etzadroxil 2.6 µg/mL。

临床怎么用

  • 对于接受该口服固定剂量组合治疗的多重耐药肠杆菌复杂性尿路感染患者,提示无需因QTc延长而常规加强ECG监测。
  • 用药期间如出现心率相关症状可结合临床评估,但现有数据未提示需特殊心脏监测。

局限性

  • 研究为健康成人I期剂量递增研究,样本量小,未涵盖真实感染患者及合并用药人群。
  • 结论基于浓度-QTc建模的预测,尚需在目标患者人群中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ceftibuten and ledaborbactam etzadroxil are being developed as an oral fixed-dose combination for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales. This study evaluated their effects on cardiac repolarization using concentration-QTc analyses. METHODS: ECG and pharmacokinetic data from two randomized, single-centre, double-blind, placebo-controlled, phase I, dose-escalation studies in healthy adults (ClinicalTrials.gov: NCT04314206 and NCT04243863) were analysed using concentration-QTc modelling. Thirty-six participants were randomized to the ceftibuten study (27 active, nine placebo) and 48 to the ledaborbactam etzadroxil study (36 active, 12 placebo). Linear mixed-effects models characterized the relationship between plasma concentrations and placebo-corrected change from baseline in Fridericia-corrected QT interval (ΔΔQTcF). Model-based predictions estimated QTc effects across observed and clinically relevant plasma concentrations. RESULTS: Neither agent produced clinically relevant changes in ECG parameters. Concentration-QTc analyses demonstrated no statistically or clinically meaningful relationship between plasma concentrations and ΔΔQTcF. An effect on ΔΔQTcF exceeding the regulatory threshold of 10 ms could be excluded at plasma concentrations up to 44 µg/mL for cis-ceftibuten (the predominant and more potent isomer), 2.2 µg/mL for trans-ceftibuten, 30.3 µg/mL for ledaborbactam (active drug), and 2.6 µg/mL for ledaborbactam etzadroxil (prodrug). A small, transient, not clinically relevant increase in heart rate was observed with ceftibuten, whereas ledaborbactam etzadroxil had no clinically meaningful effect on heart rate. CONCLUSIONS: Ceftibuten and ledaborbactam etzadroxil demonstrated no clinically relevant effects on cardiac repolarization or ECG parameters. Concentration-QTc analyses excluded clinically meaningful QTc effects at and above anticipated therapeutic plasma concentrations, supporting the cardiac safety profile of this oral fixed-dose combination.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Darpo B, Xue H, Hamed KA, et al. No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies. J Antimicrob Chemother. 2026. PMID: 42920101. doi:10.1093/jac/dkag365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。